Progression of IgA gammopathy to myeloma following infliximab treatment for pyoderma gangrenosum

Authors


  • Conflict of interest: none declared.

Dr Mohammed Shareef, Department of Dermatology, York Hospital, York Hospital NHS Trust, York, North Yorkshire YO31 8HE, UK
E-mail: m.shareef@nhs.net

Summary

Pyoderma gangrenosum (PG) may be associated with inflammatory disorders and haematological conditions such as monoclonal gammopathy of uncertain significance (MGUS). We report the case of a 53-year old man who had PG and MGUS. After treatment with infliximab for the PG, he developed myeloma. The course of events in this case suggests that infliximab facilitated the progression from MGUS to myeloma.

Ancillary